INTRODUCTIONThe potential curative role of surgery for primary non‐metastatic retroperitoneal sarcomas (RPS), is incontrovertible. However, the evidence for the addition of radiotherapy (RT) to radical surgery, as has been established for sarcomas arising in the extremities, is currently lacking and the results of the EORTC‐STBSG 62092‐22092 (NCT01344018) study addressing this question are eagerly awaited. Therefore, close collaboration and discussion between surgeons and radiation oncologists is important as the objective is to optimally combine these two treatment modalities. To date, the use of RT for the treatment of RPS is highly variable. In a population based study on 2348 RPS cases, Porter et al reported in 2006 that in general practice outside the setting of clinical trials only 25.9% of patients received RT and of these 85.5% were treated postoperatively (PORT). In the Surveillance, Epidemiology, and End Results (SEER) database, published in 2015, 30% received RT and all of them PORT. In the multi‐institutional series published by Gronchi et al in 2016, 32% of 1007 patients received any form of RT, but interestingly 72% of them were treated preoperatively. Although variable, there seems to be a time‐shift towards more preoperative RT in recent years.Given the rarity of sarcoma and complexity
Journal of Surgical Oncology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud